Study of the PKMYT1 Inhibitor RP-6306 in Combination with Gemcitabine for the Treatment of Advanced Solid Tumors (MAGNETIC Study)

Recruiting
18 years - 99 years
All
Phase 1
15 participants needed
1 Location

Brief description of study

The purpose of this research study is to: • Test how safe RP-6306 and gemcitabine are when given together at different doses and on different schedules • Test how well RP-6306 and gemcitabine work together to shrink cancer in the body RP-6306 is a PKMYT1 inhibitor that is designed to stop certain cancer cells from growing. Gemcitabine is an approved drug for many different types of cancer. It works by stopping cells from growing and dividing. Gemcitabine is given through an IV once each week for 2 weeks in a row and then there is a break for 1 week. This pattern of treatment will continue in 3-week cycles. Each IV treatment will take approximately 30 minutes.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Cancer
  • Age: 18 years - 99 years
  • Gender: All
Updated on 04 Aug 2024. Study ID: 850332

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center